AAArne Auste

Arne Auste

*This is an algorithmically generated author record based on publicly available information.

Arne Auste has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Minor differences in the untranslated regions of measles vector additional transcription units are reflected by differential immunogenicity of encoded MERS-CoV Spike antigen

    by Vishaka Tiwarekar, Aileen Ebenig, Yvonne Predota, Sabrina Schrauf, Cindy Hörner, Mona V. Lange, Mohamed R. Gadalla, Arne Auste, Csaba Miskey, Samada Muraleedharan, et al.

    The recombinant measles virus (MeV) is among those vaccine platform technologies, which are tested for the fast generation of effective vaccines against other pathogens, such as emerging virus diseases. Different live-attenuated vaccine strains have become available as backbones, with few differences. Here, we analyze how minor differences of recombinant Moraten (MV vac2 ) or Schwarz (MV Schw ) constructs have an impact on the performance of respective derived Middle East respiratory syndrome (MERS) vaccine candidates. MV vac2 or MV Schw viruses, both encoding the Spike glycoprotein (S) of the MERS-coronavirus (MERS-CoV) in an additional transcription unit (ATU) between the hemagglutinin gene and the polymerase gene L cassette, were tested. Both robustly expressed the additional gene. However, approximately twofold to threefold higher amounts of S proteins were observed in cells infected by the MV Schw -MERS-S(H) virus, correlating with the same relative ratio of S mRNA found in these cells. Exchange of the short genomic 3′ UTR ATU sequence in MV vac2 against the sequence in MV Schw enhanced gene expression by about the same factor and demonstrates causality. MeV-susceptible IFNAR −/− -CD46Ge mice vaccinated with either candidate reveal that higher relative S antigen expression by MV Schw -MERS-S(H) tended toward induction of higher specific antibody titers, but lower numbers of S antigen-specific T cells. In subsequent challenge experiments, both candidates were effective. Thus, minor differences in the genetic composition of recombinant MeV’s ATU may modulate the gene expression pattern of additionally encoded proteins that are reflected by changes in the respective immunogenicities, but which were not decisive for protection in the chosen disease model. IMPORTANCE: In case of emerging or re-emerging infections, vaccine platform technologies are needed to rapidly develop effective vaccines to aid public healthcare in pandemics. Besides mRNA vaccines, also viral platform technologies, that is, the adenovirus-derived vaccines Vaxzevria and JCOVDEN, have proven to be of immense value during the COVID-19 pandemic. For future pandemics, it is crucial to understand the factors in vector design that modulate immunogenicity. This knowledge allows the tailoring of vaccine vectors to fit specific target product profiles, for example, to build vectors which trigger an accentuated T cell or, alternatively, antibody response against an antigen of interest. Our study using the live-attenuated measles vaccine backbone as a promising example is therefore crucial in demonstrating that very minor differences in the vaccine backbone can alter the antigen expression profile of the vector-antigen system and impact the relative induction of T-cell or antibody responses against the added target antigen

  • Open Access

    Population-based prevalence and screening gaps of hepatitis C, B and D, Germany, 2020 to 2021

    by Zahra Ghodratian, Katharina Grikscheit, Loraine Busetto, Benjamin Marx, Niko Kohmer, Arne Auste, Raphael Scheu, Manuela Harries, Vanessa Melhorn, Thomas Illig, et al.

    BACKGROUND: Chronic hepatitis C (HCV) and hepatitis B (HBV) viruses remain major causes of liver-related morbidity and mortality. Despite a low prevalence in Germany, migration from higher-endemic regions and screening gaps may hinder progress towards World Health Organization (WHO) 2030 elimination targets. Population-based data are needed for surveillance, screening and elimination. AIM: We aimed to estimate prevalence of HCV, HBV and hepatitis D virus (HDV) in adults in Germany. METHODS: We retrospectively analysed 10,000 serum samples from the Multilocal and Serial Prevalence Study of Antibodies against SARS-CoV-2 in Germany (MuSPAD, 2020–2021), by age and gender distribution. Samples were pooled and tested for HCV and HBV by PCR, for HBV surface antigen (HBsAg) and for antibodies against HCV and HBV. Samples positive for HBsAg were analysed for HDV. RESULTS: Active HCV infection (HCV RNA) was detected in four (0.04%; 95% CI: 0.02–0.1) persons. Seroprevalence for HCV was 0.17% (95% CI: 0.11–0.27), highest among 60–69-year-olds (0.53%). Active HBV infection (HBV DNA and/or HBsAg) was detected in 21 participants (0.21%; 95% confidence interval (CI): 0.14–0.32), peaking at 0.44% among 30–39-year-olds. No HDV infection was confirmed. CONCLUSION: Recognising that relevant high-risk groups may be underrepresented in our data, the overall HCV and HBV prevalence in Germany appears low but non-negligible. Adults under 35 years are not covered by the national health check programme for all adults aged ≥ 35 years, suggesting potential screening gaps. Systematic HDV testing among HBV-positive individuals and targeted testing strategies may support progress towards WHO elimination goals.

  • Open Access

    The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection

    by Lisa Henss, Arne Auste, Christoph Schürmann, Christin Schmidt, Christine von Rhein, Michael D. Mühlebach, Barbara S. Schnierle

    The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has caused a pandemic with tens of millions of cases and more than a million deaths. The infection causes COVID-19, a disease of the respiratory system of divergent severity. No treatment exists. Epigallocatechin-3-gallate (EGCG), the major component of green tea, has several beneficial properties, including antiviral activities. Therefore, we examined whether EGCG has antiviral activity against SARS-CoV-2. EGCG blocked not only the entry of SARS-CoV-2, but also MERS- and SARS-CoV pseudotyped lentiviral vectors and inhibited virus infections in vitro. Mechanistically, inhibition of the SARS-CoV-2 spike–receptor interaction was observed. Thus, EGCG might be suitable for use as a lead structure to develop more effective anti-COVID-19 drugs.


  • Open Access

    A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine

    by Cindy Hörner, Christoph Schürmann, Arne Auste, Aileen Ebenig, Samada Muraleedharan, Kenneth H. Dinnon, Tatjana Scholz, Maike Herrmann, Barbara S. Schnierle, Ralph S. Baric, et al.

    The COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has spread worldwide, with millions of cases and more than 1 million deaths to date. The gravity of the situation mandates accelerated efforts to identify safe and effective vaccines. Here, we generated measles virus (MeV)-based vaccine candidates expressing the SARS-CoV-2 spike glycoprotein (S). Insertion of the full-length S protein gene in two different MeV genomic positions resulted in modulated S protein expression. The variant with lower S protein expression levels was genetically stable and induced high levels of effective Th1-biased antibody and T cell responses in mice after two immunizations. In addition to neutralizing IgG antibody responses in a protective range, multifunctional CD8+ and CD4+ T cell responses with S protein-specific killing activity were detected. Upon challenge using a mouse-adapted SARS-CoV-2, virus loads in vaccinated mice were significantly lower, while vaccinated Syrian hamsters revealed protection in a harsh challenge setup using an early-passage human patient isolate. These results are highly encouraging and support further development of MeV-based COVID-19 vaccines. Significance The COVID-19 pandemic has already caused over 1 million deaths. Therefore, effective vaccine concepts are urgently needed. In search of such a concept, we have analyzed a measles virus-based vaccine candidate targeting SARS-CoV-2. Using this well-known, safe vaccine backbone, we demonstrate here induction of functional immune responses in both arms of adaptive immunity, yielding antiviral efficacy in vivo with the desired immune bias. Consequently, no immunopathologies became evident during challenge experiments. Moreover, the candidate still induces immunity against the measles, recognized as a looming second menace, when countries are forced to stop routine vaccination campaigns in the face of COVID-19. Thus, a bivalent measles-based COVID-19 vaccine could be the solution for two significant public health threats.


  • Open Access

    A Highly Immunogenic Measles Virus-based Th1-biased COVID-19 Vaccine

    by Cindy Hoerner, Christoph Schuermann, Arne Auste, Aileen Ebenig, Samada Muraleedharan, Maike Herrmann, Barbara Schnierle, Michael D. Mühlebach

    The COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has spread world-wide with millions of cases and hundreds of thousands of deaths to date. The gravity of the situation mandates accelerated efforts to identify safe and effective vaccines. Here, we generated measles virus (MeV)-based vaccine candidates expressing the SARS-CoV-2 spike glycoprotein (S). Insertion of the full-length S protein gene in two different MeV genomic positions resulted in modulated S protein expression. The variant with lower S protein expression levels was genetically stable and induced high levels of effective Th1-biased antibody and T cell responses in mice after two immunizations. In addition to neutralizing IgG antibody responses in a protective range, multifunctional CD8 + and CD4 + T cell responses with S protein-specific killing activity were detected. These results are highly encouraging and support further development of MeV-based COVID-19 vaccines. Author Contributions: CH performed research, analyzed data, and wrote the paper; CS performed research and analyzed data; AA performed research and analyzed data; AE performed research and analyzed data; SM performed research, analyzed data, and wrote the paper; MH developed the bioinformatics pipeline and analyzed data; BS contributed new reagents and concepts; MDM designed and supervised research, analyzed data and wrote the paper; all authors read, corrected and approved the final manuscript. Significance Statement: The COVID-19 pandemic has caused hundreds of thousands of deaths, yet. Therefore, effective vaccine concepts are urgently needed. In search for such a concept, we have analysed a measles virus-based vaccine candidate targeting SARS-CoV-2. Using this well known, safe vaccine backbone, we demonstrate here induction of functional immune responses in both arms of adaptive immunity with the desired immune bias. Therefore, occurrence of immunopathologies such as antibody-dependent enhancement or enhanced respiratory disease is rather unlikely. Moreover, the candidate still induces immunity against the measles, recognized as a looming second menace, when countries are entrapped to stop routine vaccination campaigns in the face of COVID-19. Thus, a bivalent measles-based COVID-19 vaccine could be the solution for two significant public health threats.